Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.53 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | GABRP | O00591 | 1/20 | 0.48 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.48 |
| ▸ | GABRE | P78334 | 1/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2518047 | 0.89 | BAZ2B (0.56) | BAZ2BBAZ2AALDH1A1GABRPGABRD | |
| SCHEMBL6242911 | 0.86 | NOTUM (0.53) | BAZ2BBAZ2AALDH1A1GABRPGABRD | |
| SCHEMBL409717 | 0.86 | BAZ2B (0.49) | BAZ2BBAZ2AALDH1A1GABRPGABRD | |
| SCHEMBL16622895 | 0.85 | BAZ2B (0.64) | BAZ2BBAZ2AALDH1A1GABRPGABRD | |
| SCHEMBL15059338 | 0.82 | BAZ2B (0.56) | BAZ2BBAZ2AALDH1A1GABRPGABRD | |
| SCHEMBL14150281 | 0.82 | BAZ2B (0.56) | BAZ2BBAZ2AALDH1A1GABRPGABRD | |
| SCHEMBL26015021 | 0.81 | BAZ2B (0.69) | BAZ2BBAZ2AALDH1A1GABRPGABRD | |
| SCHEMBL1958094 | 0.81 | BAZ2B (0.48) | BAZ2BBAZ2AALDH1A1GABRPGABRD | |
| SCHEMBL19838113 | 0.81 | BAZ2B (0.48) | BAZ2BBAZ2AALDH1A1GABRPGABRD | |
| SCHEMBL29083221 | 0.81 | BAZ2B (0.48) | BAZ2BBAZ2AALDH1A1GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4135842-B1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-23 | — | — | EP | disclosed |
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| EP-4135842-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN Pharmaceutica NV (BE) | 2023-02-22 | — | — | EP | disclosed |
| CN-115485026-A | Pyrazolo [1,2-D ] [1,2,4] triazin-2-yl-acetamides as NLRP3 inflammatory pathway inhibitors | 詹森药业有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2021209539-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-21 | — | — | WO | disclosed |
| EP-2718290-B1 | COMPOSITIONS AND METHODS FOR MODULATING A KINASE | CLEVEXEL PHARMA (FR) | 2016-05-04 | — | — | EP | disclosed |
| EP-2718290-B1 | COMPOSITIONS AND METHODS FOR MODULATING A KINASE | CLEVEXEL PHARMA (FR) | 2016-05-04 | — | — | EP | disclosed |
| US-8937065-B2 | Compositions and methods for modulating a kinase | CLEVEXEL PHARMA (FR) | 2015-01-20 | — | — | US | disclosed |
| EP-1142872-B1 | AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES | SHIONOGI & CO (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7098201-B2 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-6984734-B2 | Cyclo[n]pyrroles and methods thereto | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-01-10 | — | — | US | disclosed |
| US-20040002485-A1 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | FUJISHITA TOSHIO (JP) | 2004-01-01 | — | — | US | disclosed |
| US-20030229131-A1 | Cyclo[n]pyrroles and methods thereto | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-12-11 | — | — | US | disclosed |
| US-6645956-B1 | 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment | SHIONOGI & CO., LTD. (JP) | 2003-11-11 | — | — | US | disclosed |
| US-6620841-B1 | Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) | SHIONOGI & CO., LTD. (JP) | 2003-09-16 | — | — | US | disclosed |
| WO-2003072581-A1 | CYCLO[N]PYRROLES AND METHODS THERETO | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-09-04 | — | — | WO | disclosed |
| CN-1335834-A | Aromatic heterocyclic compounds having HIV integrase inhibitory activity | SHIONOGI & CO (JP) | 2002-02-13 | — | — | CN | disclosed |
| EP-1142872-A1 | AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES | SHIONOGI & CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002485-A1 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | RCOR1, BCOR, CYP8B1 | BAZ2B 468/4885BAZ2A 511/4885ALDH1A1 980/4885 |
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | NLRP3, NLRP1, IL1B | BAZ2B 295/4885BAZ2A 256/4885ALDH1A1 898/4885 |
| US-20030229131-A1 | Cyclo[n]pyrroles and methods thereto | PPOX, QPCT, PPIE | BAZ2B 4744/4885BAZ2A 4746/4885ALDH1A1 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.